Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Israel Medical Association Journal : IMAJ|September 10, 2024
Can Blood Inflammatory Markers Identify Pregnant Women with Preeclampsia? Still a Controversial IssueAndrei Braester, Artyom Bilyk, Celia Suriu, et al.
Israel Journal of Health Policy Research|December 13, 2017
Physicians' lack of knowledge - a possible reason for red blood cell transfusion overuse?Roni Rahav Koren, Celia Suriu, Orly Yakir, et al.
Experimental Hematology|April 30, 2018
Elevated serum BDNF levels are associated with favorable outcome in CLL patients: Possible link to CXCR4 downregulationDavid Azoulay, Yair Herishanu, Mika Shapiro, et al.
Leukemia Research|November 10, 2020
Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myelomaHadas Rabani, Mira Ziv, Noa Lavi, et al.
International Journal of Laboratory Hematology|August 30, 2023
The role of blood inflammatory markers in the preoperative diagnosis of acute appendicitisAlper Adir, Andrei Braester, Perelstein Natalia, et al.
Leukemia & Lymphoma|September 15, 2023
Ethnic disparities in presentation but not outcome in multiple myeloma patients: a multicenter retrospective study in Northern IsraelNajib Dally, Myriam Baranes, Luiza Akria, et al.
International Journal of Molecular Sciences|January 11, 2024
The Involvement of LAG-3<sup>positive</sup> Plasma Cells in the Development of Multiple MyelomaNatalia Kreiniz, Nasren Eiza, Tamar Tadmor, et al.
American Journal of Hematology|April 1, 2018
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective studyYael C Cohen, Avi Saranga, Moshe E Gatt, et al.
British Journal of Haematology|November 17, 2015
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational studyEli Muchtar, Moshe E Gatt, Ory Rouvio, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 7, 2020
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life StudyEfrat Luttwak, Moshe E Gatt, Eyal Lebel, et al.
Pageof 2